<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01511809</url>
  </required_header>
  <id_info>
    <org_study_id>MODAt</org_study_id>
    <nct_id>NCT01511809</nct_id>
  </id_info>
  <brief_title>Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression</brief_title>
  <official_title>Efficacy of Atazanavir / Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression. Randomized, Open Label Non Inferiority Trial. A Phase 3 Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ospedale San Raffaele</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess whether Atazanavir/ritonavir monotherapy provides a non-inferior
      proportion of virological efficacy with respect to ATV/RTV + 2 NRTIs in patients with stable
      suppressed viremia and no prior virologic failures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised (1:1), multicentre, comparative, parallel-group, prospective, open
      label, non-inferiority controlled clinical trial.

      Enrolled patients, taking an ATV/r based HAART and with stable HIV-RNA &lt; 50c/ml (24 weeks),
      will be randomized to:

        -  continue the same regimen ATV/RTV 300mg/100mg OD plus 2 NRTIs (according to the specific
           dosing schedule) as backbone (HAART arm) with ATV/r

        -  or simplify therapy to ATV/RTV 300mg/100mg OD as monotherapy (Monotherapy arm) with
           ATV/r The study follow up will be 96 weeks after randomization and primary objective
           will be evaluated at week 48.

      Patients will be followed every 4 weeks for the first 16 weeks, and then every 8 weeks until
      week 48, then every 12 weeks until week 96 or discontinuation ; at each visit the following
      evaluations will be performed:

        -  clinical assessment.

        -  routine laboratory tests (hematological tests and hematochemistry) including creatinine,
           phosphorus, calcium, alkaline phosphatase, gammaGT; urine analysis, lipid profile, level
           of HIV-RNA and CD4 cell counts.

      During follow-up, at randomization, week 48, week 96 or discontinuation, patients will
      additionally undergo:

        -  Fat redistribution evaluation by DEXA (dual-energy X-ray absorptiometry

        -  Vertebral and femoral bone mineral density evaluation by DEXA.

        -  ECG;

        -  Glicate haemoglobin.

        -  Adherence assessment (questionnaire and/or pills counts).

        -  Neurocognitive evaluation [HIV-associated neurocognitive disorders (HANDs) evaluated by
           validated neuropsychological tests].

      In case of viral rebound (defined as 2 consecutive measurement of HIV-RNA &gt; 50 c/ml) patients
      will be immediately contacted in order to perform genotypic tests. Furthermore a plasma PK
      analysis will also be performed. Any patients with virological rebound will be selected for a
      reintensification therapy with NRTIs and if not suppressed after 12 weeks they will be
      discontinued.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients With Treatment Failure (TF)</measure>
    <time_frame>Up to week 48</time_frame>
    <description>Proportion of patients with treatment failure defined as having one of the following events: confirmed viral rebound (CVR) or treatment discontinuation for any cause. CVR was established when 2 consecutive viral load values (HIV-1 RNA)&gt;50 copies/mL occurred within 2 weeks during follow-up. In case of CVR, patients treated with atazanavir/ritonavir monotherapy had to re-introduce their previous 2NRTIs (re-intensification) and, if not suppressed (HIV-1 RNA &lt;50 copies /ml) after 12 weeks, discontinued from the study. Re-intensification was considered as treatment failure in the primary analysis conducted according to the intention-to-treat principle (intention-to-treat analysis with re-intensification equal failure, ITT=Failure) while it was not in the secondary analysis (intention-to-treat analysis with re-intensification equal success, ITT=Success).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy and Safety</measure>
    <time_frame>week 96</time_frame>
    <description>Proportion of pts with confirmed virological and treatment failure at w96. Change in CD4 cell counts.
Occurrence of viral resistance to atazanavir in pts with confirmed virologic failure.
Proportion of pts with adverse events, with ≥grade 2 adverse events or abnormal laboratory tests, proportion of pts with side effects leading to discontinuation.
Body fat redistribution and vertebral and femoral bone mineral density. Adherence changes; changes in HIV-associated neurocognitive disorders. Difference in levels of activated Tcells and pro-inflammatory cytokines between treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Atazanavir/ritonavir monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will simplify therapy to ATV/RTV 300mg/100mg OD as monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atazanavir/ritonavir triple therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will continue the same regimen ATV/RTV 300mg/100mg OD plus 2 NRTIs as backbone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir/ritonavir monotherapy</intervention_name>
    <description>Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.</description>
    <arm_group_label>Atazanavir/ritonavir monotherapy</arm_group_label>
    <other_name>ATV/r monotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infected patients

          -  age &gt; 18 years

          -  On treatment with ATV/r plus 2 NRTIs for at least 48 weeks

          -  Virological suppression (HIV-RNA&lt;50 c/ml) by at least 24 weeks with ATV/r plus 2 NRTIs

          -  No virologic failure after the initiation of the first antiretroviral therapy.
             Previous treatment changes due to toxicity or treatment simplifications will be
             permitted only if occurred with documented virological suppression.

          -  CD4 cells nadir &gt;100 cells/µL

          -  PPI and H2-receptor antagonists as follows: the proton-pump inhibitors should not be
             used; if H2-receptor antagonists are co-administered, a dose equivalent to famotidine
             20 mg BID should not be exceeded.

        Exclusion Criteria:

          -  Pregnancy and breast feeding women

          -  AIDS defining events

          -  Evidence of active HBV infection (HBsAg positive)

          -  Previous virological failure

          -  History of resistance to ATV

          -  Use of contraindicated medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriano Lazzarin, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale San Raffaele</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Infectious Diseases Department Fondazione Centro San Raffaele</name>
      <address>
        <city>Milan</city>
        <state>Lombardia</state>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, Norton M, Rouzioux C, Taburet AM, Cohen-Codar I, Van PN, Chauvin JP. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS. 2008 Jan 30;22(3):385-93. doi: 10.1097/QAD.0b013e3282f3f16d.</citation>
    <PMID>18195565</PMID>
  </reference>
  <reference>
    <citation>Cameron DW, da Silva BA, Arribas JR, Myers RA, Bellos NC, Gilmore N, King MS, Bernstein BM, Brun SC, Hanna GJ. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis. 2008 Jul 15;198(2):234-40. doi: 10.1086/589622.</citation>
    <PMID>18540803</PMID>
  </reference>
  <reference>
    <citation>Pulido F, Arribas JR, Delgado R, Cabrero E, González-García J, Pérez-Elias MJ, Arranz A, Portilla J, Pasquau J, Iribarren JA, Rubio R, Norton M; OK04 Study Group. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS. 2008 Jan 11;22(2):F1-9.</citation>
    <PMID>18097218</PMID>
  </reference>
  <reference>
    <citation>Arribas JR, Delgado R, Arranz A, Muñoz R, Portilla J, Pasquau J, Pérez-Elias MJ, Iribarren JA, Rubio R, Ocampo A, Sánchez-Conde M, Knobel H, Arazo P, Sanz J, López-Aldeguer J, Montes ML, Pulido F; OK04 Study Group. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):147-52. doi: 10.1097/QAI.0b013e3181a56de5.</citation>
    <PMID>19349870</PMID>
  </reference>
  <reference>
    <citation>Arribas JR, Horban A, Gerstoft J, Fätkenheuer G, Nelson M, Clumeck N, Pulido F, Hill A, van Delft Y, Stark T, Moecklinghoff C. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 2010 Jan 16;24(2):223-30. doi: 10.1097/QAD.0b013e3283348944.</citation>
    <PMID>20010070</PMID>
  </reference>
  <reference>
    <citation>Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girard PM, Molina JM, Hoen B, Pakianather S, Peytavin G, Marcelin AG, Flandre P. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 2010 Sep 24;24(15):2365-74. doi: 10.1097/QAD.0b013e32833dec20.</citation>
    <PMID>20802297</PMID>
  </reference>
  <reference>
    <citation>Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, Godfrey C, Bastow B, Ray MG, Wang H, Coombs RW, McKinnon J, Mellors JW; AIDS Clinical Trials Group 5201 Study Team. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA. 2006 Aug 16;296(7):806-14.</citation>
    <PMID>16905786</PMID>
  </reference>
  <reference>
    <citation>Karlström O, Josephson F, Sönnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):417-22.</citation>
    <PMID>17159658</PMID>
  </reference>
  <reference>
    <citation>Wilkin TJ, McKinnon JE, DiRienzo AG, Mollan K, Fletcher CV, Margolis DM, Bastow B, Thal G, Woodward W, Godfrey C, Wiegand A, Maldarelli F, Palmer S, Coffin JM, Mellors JW, Swindells S. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis. 2009 Mar 15;199(6):866-71. doi: 10.1086/597119.</citation>
    <PMID>19191590</PMID>
  </reference>
  <reference>
    <citation>Vernazza P, Daneel S, Schiffer V, Decosterd L, Fierz W, Klimkait T, Hoffmann M, Hirschel B. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS. 2007 Jun 19;21(10):1309-15.</citation>
    <PMID>17545707</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <results_first_submitted>November 7, 2014</results_first_submitted>
  <results_first_submitted_qc>November 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 24, 2014</results_first_posted>
  <last_update_submitted>January 8, 2016</last_update_submitted>
  <last_update_submitted_qc>January 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale San Raffaele</investigator_affiliation>
    <investigator_full_name>Castagna Antonella</investigator_full_name>
    <investigator_title>Co- Investigator</investigator_title>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Atazanavir/Ritonavir Monotherapy</title>
          <description>Patients will simplify therapy to ATV/RTV 300mg/100mg OD as monotherapy
Atazanavir/ritonavir monotherapy: Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Atazanavir/Ritonavir Triple Therapy</title>
          <description>Patients will continue the same regimen ATV/RTV 300mg/100mg OD plus 2 NRTIs as backbone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atazanavir/Ritonavir Monotherapy</title>
          <description>Patients will simplify therapy to ATV/RTV 300mg/100mg OD as monotherapy
Atazanavir/ritonavir monotherapy: Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Atazanavir/Ritonavir Triple Therapy</title>
          <description>Patients will continue the same regimen ATV/RTV 300mg/100mg OD plus 2 NRTIs as backbone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="103"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.4" lower_limit="35.4" upper_limit="47.7"/>
                    <measurement group_id="B2" value="41.7" lower_limit="36.6" upper_limit="49.8"/>
                    <measurement group_id="B3" value="41.5" lower_limit="35.6" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>nadir CD4+</title>
          <description>Lowest CD4+ value among those recorded since the first HIV positive test up to the start of MODAt study</description>
          <units>cells/mm3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="274" lower_limit="221" upper_limit="355"/>
                    <measurement group_id="B2" value="278" lower_limit="183" upper_limit="364"/>
                    <measurement group_id="B3" value="276" lower_limit="211" upper_limit="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years of antiretroviral treatment</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" lower_limit="16" upper_limit="47"/>
                    <measurement group_id="B2" value="25" lower_limit="18" upper_limit="54"/>
                    <measurement group_id="B3" value="25" lower_limit="17" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 RNA &lt;50 copies/ml</title>
          <description>Quantitative value of HIV-1 RNA copies/ml in plasma. HIV-1 RNA below 50 copies/ml (detection limit) is an indicator of efficacy of the antiretroviral therapy</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="10" upper_limit="49"/>
                    <measurement group_id="B2" value="18" lower_limit="12" upper_limit="49"/>
                    <measurement group_id="B3" value="19" lower_limit="11" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-RNA at ARV start</title>
          <units>copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79399" lower_limit="31046" upper_limit="183613"/>
                    <measurement group_id="B2" value="42630" lower_limit="9696" upper_limit="123700"/>
                    <measurement group_id="B3" value="59062" lower_limit="10834" upper_limit="165850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4+</title>
          <units>cells/mm3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="599" lower_limit="457" upper_limit="774"/>
                    <measurement group_id="B2" value="570" lower_limit="417" upper_limit="735"/>
                    <measurement group_id="B3" value="575" lower_limit="432" upper_limit="744"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV coinfection</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With Treatment Failure (TF)</title>
        <description>Proportion of patients with treatment failure defined as having one of the following events: confirmed viral rebound (CVR) or treatment discontinuation for any cause. CVR was established when 2 consecutive viral load values (HIV-1 RNA)&gt;50 copies/mL occurred within 2 weeks during follow-up. In case of CVR, patients treated with atazanavir/ritonavir monotherapy had to re-introduce their previous 2NRTIs (re-intensification) and, if not suppressed (HIV-1 RNA &lt;50 copies /ml) after 12 weeks, discontinued from the study. Re-intensification was considered as treatment failure in the primary analysis conducted according to the intention-to-treat principle (intention-to-treat analysis with re-intensification equal failure, ITT=Failure) while it was not in the secondary analysis (intention-to-treat analysis with re-intensification equal success, ITT=Success).</description>
        <time_frame>Up to week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir/Ritonavir Monotherapy</title>
            <description>Patients will simplify therapy to ATV/RTV 300mg/100mg OD as monotherapy
Atazanavir/ritonavir monotherapy: Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir/Ritonavir Triple Therapy</title>
            <description>Patients will continue the same regimen ATV/RTV 300mg/100mg OD plus 2 NRTIs as backbone</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Treatment Failure (TF)</title>
          <description>Proportion of patients with treatment failure defined as having one of the following events: confirmed viral rebound (CVR) or treatment discontinuation for any cause. CVR was established when 2 consecutive viral load values (HIV-1 RNA)&gt;50 copies/mL occurred within 2 weeks during follow-up. In case of CVR, patients treated with atazanavir/ritonavir monotherapy had to re-introduce their previous 2NRTIs (re-intensification) and, if not suppressed (HIV-1 RNA &lt;50 copies /ml) after 12 weeks, discontinued from the study. Re-intensification was considered as treatment failure in the primary analysis conducted according to the intention-to-treat principle (intention-to-treat analysis with re-intensification equal failure, ITT=Failure) while it was not in the secondary analysis (intention-to-treat analysis with re-intensification equal success, ITT=Success).</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ITT=Failure analysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5"/>
                    <measurement group_id="O2" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITT=Success analysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Here are reported the results of the 48-week interim analyses according to the intention-to-treat (ITT) principle. ITT=F (with re-intensification=failure) and the ITT=S (with re-intensification=success) treatment failure results are shown.
Based on the efficacy data review, in June 2013, an independent Data and Safety Monitoring Board (DSMB) recommended to stop further patients’ enrolment and to follow-up the enrolled patients until 96 weeks, after having signed an updated informed consent.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A lower limit of the 95% confidence interval of the difference between the two proportions of treatment failure (triple therapy-monotherapy) below the pre-specified margin of non-inferiority of -10% established inferiority. A sample size of 342 patients (171 per treatment arm) provided 80% power (one-sided, alpha 0.05) to establish non-inferiority of ATV/r monotherapy as compared to ATV/r triple therapy with an overall treatment failure (TF) rate of 15% at week 48.</non_inferiority_desc>
            <param_type>difference between TF proportions</param_type>
            <param_value>15</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy and Safety</title>
        <description>Proportion of pts with confirmed virological and treatment failure at w96. Change in CD4 cell counts.
Occurrence of viral resistance to atazanavir in pts with confirmed virologic failure.
Proportion of pts with adverse events, with ≥grade 2 adverse events or abnormal laboratory tests, proportion of pts with side effects leading to discontinuation.
Body fat redistribution and vertebral and femoral bone mineral density. Adherence changes; changes in HIV-associated neurocognitive disorders. Difference in levels of activated Tcells and pro-inflammatory cytokines between treatment groups.</description>
        <time_frame>week 96</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to week 48</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Atazanavir/Ritonavir Monotherapy</title>
          <description>Patients will simplify therapy to ATV/RTV 300mg/100mg OD as monotherapy
Atazanavir/ritonavir monotherapy: Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Atazanavir/Ritonavir Triple Therapy</title>
          <description>Patients will continue the same regimen ATV/RTV 300mg/100mg OD plus 2 NRTIs as backbone</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>acute coronary stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>left basal pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>acute hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>cholecystitis due to cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>nephrolitiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>gross haematuria with proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Antonella Castagna</name_or_title>
      <organization>Ospedale San Raffaele</organization>
      <phone>00390226437934</phone>
      <email>castagna.antonella1@hsr.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

